Advances in Collaborative Practice for Patients With Head and Neck Cancers
Presented by Robert Haddad, MD, and Jason Glass, ACNP-BC
Dana-Farber Cancer Institute, Boston, Massachusetts
Presenters’ disclosures of potential conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2017;8:261–265 |
© 2017 Harborside Press®
Head and neck cancer care is complex, and there are limited treatment options; over the past decade only one new therapy received FDA approval. However, as in other tumor types, the landscape is changing with the recent emergence of newer targeted therapies and immunotherapies.
For access to the full length article, please sign in